The Lung Cancer Drug That Fell 1.5 Months Short of Mattering

Where the Numbers Fell Apart

FURVENT enrolled 398 patients across the globe. It was a three-arm study: one group got 240 mg of firmonertinib daily, another got 160 mg, and a third got standard platinum-based chemotherapy with pemetrexed (the current go-to combo for these patients).

The trial's main question was straightforward: does firmonertinib keep cancer from progressing longer than chemo? This metric, called progression-free survival (PFS), was assessed by independent reviewers who didn't know which treatment patients received.

The 240 mg dose showed a median PFS of 11.0 months, compared to 9.5 months for chemotherapy. That's a real difference in absolute terms, but the p-value came in at 0.0654. In statistics, you typically need that number below 0.05 to declare a win. Think of it like a basketball game where you need to win by two points to advance, and you only won by one. The scoreboard looks good, but the rules say you're out.

The lower 160 mg dose fared even worse, with a median PFS of just 8.4 months, actually trailing the chemo arm.

ArriVent itself acknowledged the improvement wasn't meaningful. When the company designing the trial says the results aren't good enough, that's about as definitive as it gets.

J&J Already Owns This Neighborhood

Even if firmonertinib had squeaked past the statistical finish line, it would have walked into a brutal competitive landscape. Johnson & Johnson's Rybrevant (amivantamab) is already approved for EGFR exon 20 insertion NSCLC, both as a first-line treatment combined with chemotherapy and as a standalone option after chemo fails.

J&J hasn't been sitting still, either. In 2026, the FDA approved a once-monthly subcutaneous formulation of Rybrevant, making it more convenient for patients who'd rather not spend hours in an infusion chair. J&J also pairs Rybrevant with lazertinib (branded as Lazcluze) for broader EGFR-mutated lung cancer, directly challenging Tagrisso's long reign as the default first-line treatment.

For ArriVent, the competitive math was already daunting before the trial failed. Now it's essentially impossible. You can't walk into a market where a pharma giant has multiple approved formulations and say, "Hey, our drug that missed its primary endpoint would like a seat at the table."

The One-Drug Company Problem

ArriVent's collapse illustrates a pattern that keeps repeating in biotech: the single-asset gamble. When a company's entire valuation rests on one drug and one pivotal readout, the downside is catastrophic. There's no diversified pipeline to cushion the blow, no second act waiting in the wings.

This isn't a new lesson, but the market keeps learning it the hard way. In 2025 and 2026 alone, several high-profile Phase 3 oncology programs have imploded. Arcus and Gilead stopped their STAR-221 anti-TIGIT trial for futility after finding no survival benefit. Roche's tiragolumab program (SKYSCRAPER-01) collapsed amid questions about biomarker strategy. BeiGene pulled the plug on ociperlimab after a late-stage study looked unlikely to succeed.

The common thread? Strong early data that didn't translate into Phase 3 wins. It's the biotech version of a Hollywood trailer that's better than the movie. Phase 2 results generate hype, investors pile in, and then the randomized, controlled, rigorously measured Phase 3 trial delivers a reality check.

What Happens Next

ArriVent still has some clinical programs running, including a Phase 1b study of firmonertinib in other uncommon EGFR mutations. But the FURVENT failure guts the company's near-term story. Without a clear path to FDA approval in exon 20 insertion NSCLC, the Breakthrough Therapy Designation becomes a participation trophy rather than a runway to revenue.

For patients with EGFR exon 20 insertion lung cancer, the competitive field just got smaller. That's not necessarily bad news; it means J&J's Rybrevant faces less pressure to improve, but it also means fewer alternatives if Rybrevant doesn't work for a given patient.

And for biotech investors, ArriVent joins a growing list of cautionary tales. The lesson isn't that you should never bet on single-asset biotechs. The lesson is that you should size those bets knowing that the distance between "almost worked" and "worked" can be worth billions of dollars, and sometimes that gap is only 1.5 months wide.

The $3.95 Million Drug That Costs More Than Most Houses

Ultragenyx just priced its new gene therapy Fayuvi at $3.95 million per patient, making it the second most expensive drug in the world. It's a one-time treatment for a fatal childhood brain disease with zero alternatives, and it's reigniting the fiercest debate in biotech: who pays for a genetic cure?